Therefore, the anti-tumor effects of scFv-OA2-siRAPSYN were definitively confirmed in the cell line-based mouse model, and the advantage of anti-CD79B-scFv conjugation was verified in vivo. This evidence concerns the gene CD79B and neoplasm.